AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 512
(A-22)

Introduced by: Mississippi

Subject: Scheduling and Banning the Sale of Tianeptine in the United States

Referred to: Reference Committee E

Whereas, While Tianeptine is approved in some countries to treat depression and anxiety, it is an unapproved drug in the United States due to safety concerns; and

Whereas, Tianeptine is legally sold over the counter in the United States commonly in gas stations and convenience stores; and

Whereas, The U.S. Food and Drug Administration (FDA) is warning consumers they may inadvertently find themselves addicted to tianeptine and should avoid all products containing it, especially those that claim to treat opioid use disorder since reliance on these products may delay appropriate treatment and put consumers at greater risk of overdose and death; and

Whereas, The FDA is aware of several serious adverse event reports including agitation, drowsiness, confusion, sweating, rapid heartbeat, high blood pressure, confusion, nausea, vomiting, slowed or stopped breathing, coma, and death associated with tianeptine and these reports are increasing with poison control centers cases nationwide from 11 cases between 2000 and 2013 to 151 in 2020 alone; and

Whereas, Tianeptine is not approved in the United States for any medical use; and

Whereas, Tianeptine is currently widely available for sale to the public, presenting safety risks and risk of abuse; and

Whereas, Tianeptine is not currently controlled under the Controlled Substances Act, but is being scheduled on a state-by-state basis as a Schedule II controlled substance, as recently passed in Alabama and Michigan. Schedule II drugs by definition mean that a substance may lead to severe psychological or physical dependence and joins other substances such as morphine, methamphetamine, cocaine, methadone, hydrocodone, fentanyl, and phencyclidine (PCP) in that class; therefore be it

RESOLVED, That our American Medical Association advocate to schedule Tianeptine as Schedule II whilst supporting research into the safety and efficacy of the substance (Directive to Take Action); and be it further

RESOLVED, That our AMA advocate to ban the sale of Tianeptine directly to the public. (Directive to Take Action)

Fiscal Note: Not yet determined

Received: 04/07/22

https://www.fda.gov/consumers/consumer-updates/tianeptine-products-linked-serious-harm-overdoses-death
https://en.wikipedia.org/wiki/Tianeptine